For Immediate Release
Chicago, IL – July 12, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Berkshire Hathaway Inc. (
BRK.B
), The Walt Disney Co.
DIS
, CVS Health Corp.
CVS
, Citigroup Inc.
C
, and Canadian National Railway Co.
CNI
.
Here are highlights from Monday’s Analyst Blog:
Top Research Reports for Berkshire Hathaway, Walt Disney and CVS
The Zacks Research Daily presents the best research output of our analyst team. Today’s Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc., The Walt Disney Co. and CVS Health Corp.. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can
see all of today’s research reports here >>>
Berkshire Hathaway
shares have outperformed the Zacks Insurance – Property and Casualty industry over the past year (+0.3% vs. -5.0%). The Zacks analyst believes that Berkshire’s inorganic growth story remains impressive with strategic acquisitions.
A strong cash position supports earnings-accretive bolt-on buyouts and indicates the company’s financial flexibility. Continued insurance business growth fuels increase in float, drive earnings and generates maximum return on equity. The non-insurance businesses are delivering improved results with increased revenues over the past few years. A sturdy capital level provides further impetus.
However, exposure to catastrophe loss induces earnings volatility and also affects the property and casualty underwriting results of Berkshire. Huge capital expenditures remain a headwind for the company.
(You can
read the full research report on Berkshire Hathaway here >>>
)
Walt Disney
shares have declined -38.1% over the year to date period against the Zacks Media Conglomerates industry’s decline of -32.0%. The Zacks analyst believes that Disney+’s profitability is expected to be negatively impacted by higher investments in content, which will drive up programming and production costs at Media and Entertainment Distribution. Closure of its Asian theme park due to COVID-19 doesn’t bode well for the Parks, Experiences and Products top-line growth.
Nevertheless, the company benefits from the growing popularity of Disney+, owing to a strong content portfolio and a cheaper bundle offering. Availability in the Nordics, Latin America and other Asian territories is helping it in expanding its user base. Revival in Parks business also holds promise in the long haul.
(You can
read the full research report on Walt Disney here >>>
)
CVS Health
shares have outperformed the Zacks Retail – Pharmacies and Drug Stores industry over the past year (+17.7% vs. +4.9%). The Zacks analyst believes that the company’s continued investments to address housing insecurities and enhance access to health care services in underserved communities seem encouraging.
The raised earnings per share (EPS) guidance for 2022 buoys optimism. In fact, CVS Health exited the first quarter of 2022 with earnings and revenues beating the Zacks Consensus Estimate.
Yet, the contraction of margins on escalating costs does not bode well. The decline in operating profit due to the pending litigation with the state of Florida to settle all opioid claims against CVS Health raises apprehension.
(You can
read the full research report on CVS here >>>
)
Other noteworthy reports we are featuring today include Citigroup Inc., and Canadian National Railway Co..
Why Haven’t You Looked at Zacks’ Top Stocks?
Our 5 best-performing strategies have blown away the S&P’s impressive +28.8% gain in 2021. Amazingly, they soared
+40.3%, +48.2%, +67.6%, +94.4%,
and
+95.3%
. Today you can access their live picks without cost or obligation.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss
.
This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit
https://www.zacks.com/performance
for information about the performance numbers displayed in this press release.
Zacks Names “Single Best Pick to Double”
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
